Archives of Medical Research
Volume 40, Issue 7 , Pages 625-634 , October 2009

Study on TP53 Codon 72 Polymorphisms with Oral Carcinoma Susceptibility

  • Xian-Lu Zhuo

      Affiliations

    • Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, China
    • Department of Otolaryngology, Guiyang Medical College, Guiyang, Guizhou Province, China
    • ,
  • Qi Li

      Affiliations

    • Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Yan Zhou

      Affiliations

    • Department of Stomatology, Xinqiao Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Lei Cai

      Affiliations

    • Institute of Hepatobiliary Surgery, Southwest Hospital,Third Military Medical University, Chongqing, China
    • ,
  • Zhao-Lan Xiang

      Affiliations

    • Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Wei Yuan

      Affiliations

    • Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Xue-Yuan Zhang

      Affiliations

    • Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, China
    • Corresponding Author InformationAddress reprint requests to: Xue-Yuan Zhang, Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China; Phone and Fax: (+86) 23 68754405

Received 16 June 2009 ,Accepted 7 September 2009.

References 

  1. Zhuo W, Wang Y, Zhuo X, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. Cancer Invest. 2009;27:86–95
  2. Yapijakis C, Kechagiadakis M, Nkenke E, et al. Association of leptin −2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer. J Cancer Res Clin Oncol. 2008;doi: 10.1007/s00432-008-0494-z
  3. Vairaktaris E, Serefoglou Z, Avgoustidis D, et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol. 2008;doi:10.1016/j.oraloncology.2008.05.003
  4. Tseng HC, Tsai MH, Chiu CF, et al. Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res. 2008;28:1687–1691
  5. Cheng CY, Chang CS, Liu CJ, et al. Vascular endothelial growth factor 936 C/T polymorphism is associated with vascular invasion in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:79–84
  6. Bumroongkit K, Rannala B, Traisathit P, et al. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. Cancer Genet Cytogenet. 2008;185:20–27
  7. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer. 2008;8:357
  8. Mahdavinia M, Bishehsari F, Verginelli F, et al. P53 mutations in colorectal cancer from northern Iran: relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol. 2008;216:543–550
  9. Hassan NM, Tada M, Hamada J, et al. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. Cancer Lett. 2008;270:108–119
  10. Kuo MY, Huang JS, Hsu HC, et al. Infrequent p53 mutations in patients with areca quid chewing-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med. 1999;28:221–225
  11. Acha-Sagredo A, Ruesga MT, Rodriguez C, et al. p53 mutation is rare in oral mucosa brushings from patients previously treated for a head and neck squamous cell carcinoma. Oral Oncol doi:doi:10.1016/j.oraloncology. 2008.10.002
  12. Ara S, Lee PS, Hansen MF, et al. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18:4961
  13. Shen H, Solari A, Wang X, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11:1115–1120
  14. Bonafé M, Ceccarelli C, Farabegoli F, et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res. 2003;9:4860–4864
  15. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234
  16. Wang YC, Lee HS, Chen SK, et al. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226–230
  17. Yu MW, Yang SY, Chiu YH, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697–702
  18. Mabrouk I, Baccouche S, El-Abed R, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2003;1010:764–770
  19. Munafò MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39–44
  20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  21. Ji X, Neumann AS, Sturgis EM, et al. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis. 2008;29:875–879
  22. Cortezzi SS, Provazzi PJ, Sobrinho JS, et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cytogenet. 2004;150:44–49
  23. Schneider-Stock R, Mawrin C, Motsch C, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol. 2004;164:1233–1241
  24. Tandle AT, Sanghvi V, Saranath D. Determination of p53 genotypes in oral cancer patients from India. Br J Cancer. 2001;84:739–742
  25. Drummond SN, De Marco L, Pordeus Ide A, et al. TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res. 2002;22:3379–3381
  26. Kietthubthew S, Sriplung H, Au WW, et al. The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev. 2003;4:209–214
  27. Bau DT, Tsai MH, Lo YL, et al. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. Anticancer Res. 2007;27:1559–1564
  28. Summersgill KF, Smith EM, Kirchner HL, et al. p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:334–339
  29. Shen H, Zheng Y, Sturgis EM, et al. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183:123–130
  30. Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer. 2002;97:649–653
  31. Katiyar S, Thelma BK, Murthy NS, et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem. 2003;252:117–124
  32. Hsieh LL, Huang TH, Chen IH, et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer. 2005;92:30–35
  33. Kuroda Y, Nakao H, Ikemura K, et al. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol. 2007;43:1043–1048
  34. Tu HF, Chen HW, Kao SY, et al. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol. 2008;87:243–252
  35. Chen X, Sturgis EM, El-Naggar AK, et al. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008;29:2120–2125
  36. Lin YC, Huang HI, Wang LH, et al. Polymorphisms of COX-2 −765G > C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008;44:798–804
  37. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  38. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull. 1999;8:15–17
  39. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev. 2004;13:11–22
  40. Jee SH, Won SY, Yun JE, et al. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet. 2004;85:301–308
  41. Sousa H, Santos AM, Pinto D, et al. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 2007;20:731–741
  42. Zhuo XL, Cai L, Xiang ZL, et al. TP53 codon 72 polymorphisms contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res. 2009;40:299–305
  43. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18:377–385
  44. Zhou Y, Li N, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481–1486
  45. Li Y, Qiu LX, Shen XK, et al. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer. 2009;doi:10.1016/j.lungcan.2008.12.009
  46. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25:1602–1611
  47. Dumont P, Leu JI, Della Pietra AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365
  48. Chang CC, Hsieh YY, Tsai FJ, et al. The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril. 2002;77:43–45
  49. Ye Y, Lippman SM, Lee JJ, et al. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer. 2008;113:2488–2495
  50. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:622–635
  51. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234

PII: S0188-4409(09)00181-7

doi: 10.1016/j.arcmed.2009.09.004

Archives of Medical Research
Volume 40, Issue 7 , Pages 625-634 , October 2009

Article Tools

* Image Usage & Resolution